JAK3-IN-11

Name: JAK3-IN-11
Brand: TargetMol
SKU: T9811
Price: 195 USD
Availability: InStock
Rating: 4.5 (1 reviews)

还可以

产品编号 T9811Cas号 2412734-00-8

JAK3- in -11 (Compound 12) 是表现出强效的、无细胞毒性、不可逆、口服活性的JAK3抑制活性，IC50值为1.7 nM，具有出色的选择性(高于其他 JAK3 亚型的588倍)，共价结合到 JAK3 的 ATP-binding pocket。 JAK3-IN-11 强烈抑制 JAK3 依赖的信号转导和T 细胞增殖，是研究自身免疫性疾病的有效工具。

JAK3-IN-11

还可以

产品编号 T9811Cas号 2412734-00-8

规格	价格	库存
25 mg	¥ 10,600	10-14周
50 mg	¥ 13,800	10-14周
100 mg	¥ 17,500	10-14周

大包装 & 定制

加入购物车

该分子属于定制产品。TargetMol拥有优秀的合成团队，经验和能力，可以为您提供高性价比的产品。但由于客观因素，研发中会存在小概率合成不成功的情况，还请理解，如您有任何问题，欢迎咨询，我们将竭诚为您服务。

实验操作小课堂

联系我们获取更多批次信息

资源下载

产品操作手册

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性

产品描述	JAK3-IN-11 (Compound 12) exhibits potent, noncytotoxic, irreversible, orally active JAK3 inhibitory activity (IC50 = 1.7 nM) with an excellent selectivity profile (>588-fold compared to other JAK isoforms), covalently binds to the ATP-binding pocket in JAK3. JAK3-IN-11 strongly inhibits JAK3-dependent signaling and T-cell proliferation which is a promising tool for studying autoimmune diseases [1].
体外活性	JAK3-IN-11 (Compound 12) (10 μM, 72 h) has no obvious cytotoxicity at a concentration of 10 μM [1]. JAK3-IN-11 (Compound 12) (72 h) shows strong inhibition for T cell proliferation with IC 50 values of 0.83 μM (anti-CD3/CD28 stimulation) and 0.77 μM (IL-2 stimulation) [1]. JAK3-IN-11 (Compound 12) (0-10 μM, 1h) abrogates IL-2 or IL-15-induced phosphorylation of STAT5 in a concentration-dependent manner [1]. JAK3-IN-11 (Compound 12) covalently binds to JAK3 and irreversibly inhibits JAK3 [1]. Cell Proliferation Assay [1] Cell Line: Mouse T cells in complete RPMI1640 medium then exposed to anti-CD3/anti-CD28 or IL-2. Concentration: Incubation Time: 72 h. Result: Displayed strong inhibition for T cell proliferation with an IC 50 values of 0.83 μM (anti-CD3/CD28 stimulation) and 0.77 μM (IL-2 stimulation), showed obvious significant immunosuppressive activity under selective inhibition of JAK3. Western Blot Analysis [1] Cell Line: Purified T cells were pre-activated coated with anti-CD3 and anti-CD28 for 72 h, then cultured with IL-2 (50 U/mL) for 36 h, then, cultured without IL-2 for 36 h Concentration: 0.01, 0.1, 1, 10 μM. Incubation Time: 1 h. Result: Abrogated IL-2 or IL-15-induced phosphorylation of STAT5 in a concentration-dependent manner.
体内活性	JAK3-IN-11 (Compound 12) (Oxazolone (OXZ)-induced DTH Balb/c mice; 0-30 mg/kg; PO, prior to and during the challenge phase, 6 days) inhibits oxazolone (OXZ)-induced delayed type hypersensitivity (DTH) responses in a dose-dependent manner [1]. Animal Model: Oxazolone (OXZ)-induced DTH Balb/c mice model [1]. Dosage: 30, 10, and 3 mg/kg. Administration: PO, prior to and during the challenge phase, 6 days. Result: Dose-dependently inhibited oxazolone (OXZ)-induced delayed-type hypersensitivity (DTH) responses. Animal Model: Male ICR mice [1]. Dosage: 30 mg/kg for oral gavage, 10 mg/kg for intravenous administration. Administration: Pharmacokinetic Analysis Result: Preliminary pharmacokinetic data of JAK3-IN-11 (Compound 12) in male ICR Mice [1] Male ICR mice, 30 mg/kg for oral gavage, 10 mg/kg for intravenous administration [1]. Compound 12 iv (10 mg/kg) po (30 mg/kg) AUC(0-t) (mg/Lh) a 1244.41 ± 77.83 889.42 ± 48.32 AUC(0-∞) (mg/Lh) 1274.41 ± 57.18 897.12 ± 56.72 MRT (0-∞) (h) b 0.73 ± 0.08 1.42 ± 0.38 Vz (L/kg) c 8.36 ± 1.83 220.42 ± 24.71 CLz (L/h/kg) d 8.15 ± 1.21 97.14 ± 20.87 t 1/2 (h) e 0.47 ± 0.06 1.52 ± 0.34 C max (mg/L) f 8763.23 ± 324.65 2008.21 ± 189.44 Bioavailability(%) g 23.82% a Area under the concentration time curve. b Mean residence time. c Volume in steady state. d Plasma clearance. e Terminal half-life. f Peak plasma concentrations. g Bioavailability = AUC 0-t (po)/AUC 0-t × 100%.